Hannah Clarke

OpenFlo incorporates a design that modifies key mechanical features of conventional Foley catheters.

VIR-5500 is a PSMA-targeted PRO-XTEN dual-masked T-cell engager entering phase 3 development for prostate cancer.

A national survey found US hospitals expanded CAUTI prevention over 20 years, but use of key catheter-removal strategies remains variable.

Based on these results, the trial protocol has been amended to move enrollment earlier in the course of disease progression.

This FAQ outlines key recommendations and practical takeaways from the AUA/SUO guideline amendment on the diagnosis and treatment of NMIBC.

The AMA issued separate codes for subfascial and subcutaneous implantation of a tibial neuromodulation device.

Exploratory analyses suggest persistent immune remodeling after aglatimagene plus radiation in localized prostate cancer.

A recap of the FDA submissions and regulatory decisions in urology from September 2026.

Robert J. Motzer, MD, discusses the significance of the belzutifan plus lenvatinib approval, adverse event management with the combination, and the evolving role of HIF-2α inhibition in ccRCC.

The phase 3 BiPASS trial is evaluating the use of 68Ga-PSMA-PET in combination with MRI for pre-biopsy prostate cancer detection.

In RTOG 3506, adding enzalutamide to standard ADT and salvage radiotherapy was associated with 2-year PFS benefit.

In the phase 3 PACE-A trial, SBRT and prostatectomy showed similar 8-year disease control in localized prostate cancer, with lower rates of urinary incontinence after SBRT.

The registrational study is designed to evaluate the diagnostic performance of 68Ga-DOTA-RM2 vs histopathology in prostate cancer.

A limited market release of SpaceOAR Flex is expected to begin in the US later this year.

The PDUFA target action date is in the fourth quarter of 2026.

The approval is supported by data from the phase 3 LITESPARK-011 trial.

Positive safety and efficacy data from 4 clinical studies supported the CE marking.

The assay is designed to enable faster pathogen identification and susceptibility testing to guide UTI management.

The safety and efficacy of vibegron are supported by data from the phase 3 COURAGE and EMPOWUR trials.

A decision is expected by the fourth quarter of 2026.

EG110A is an investigational DNA medicine under development for neurogenic detrusor overactivity with urinary incontinence.

The clearance expands access to the LigaSure vessel-sealing technology within robotic surgical workflows.

These FAQs outline key recommendations and practical takeaways from the 2026 AUA Medical Management of Kidney Stones guideline amendment.

A phase 1 study found topical sildenafil cream was linked with lower systemic exposure than oral sildenafil and was well tolerated in healthy men.

The study is assessing the safety and preliminary efficacy of CD28 co-stimulation in patients with mCRPC.

All patients have been treated in the phase 3 ENLIGHTED trial, evaluating padeliporfin VTP for low-grade upper tract urothelial carcinoma.

Martin Schoen, MD, PhD, explains how real-world evidence can help compare ARPIs and why study design and patient selection are critical to interpretation.

A randomized trial will test whether an app-guided, at-home PSA screening approach can improve prostate cancer screening among Black men.

Dabogratinib showed early activity and manageable safety in FGFR3-altered LG-IR-NMIBC, supporting advancement to a planned registrational study in the adjuvant setting.

The Zenflow Spring Implant and Delivery System has entered commercial use for BPH following its FDA approval in December 2025.